Embrace Systems Corp. EMBC 深 沪
已收盘 08-01 16:00:00 美东时间
9.96
-0.200
-1.97%
华盛通- 最 高10.13
- 今 开10.12
- 成交量 67.35万股
- 最 低 9.77
- 昨 收 10.16
- 总市值 5.82亿
- 52周最高 21.03
- 市盈率 静 7.42
- 换手率 1.15%
- 52周最低 9.20
- 委 比 22.94%
- 总股本 5844.25万
- 历史最高 34.99
- 量 比 1.17
- 振 幅 3.54%
- 历史最低 9.175
- 每 手 1
- 风险率 3.08%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多embecta to Report Fiscal Third Quarter 2025 Financial Results
Embecta Corp. will host a conference call on August 8, 2025, to discuss its fiscal third quarter 2025 financial results, provide an operational update, and answer questions. The call will begin at 8:00 a.m. ET. Participants can access the live webcast via provided links or the company’s investor relations website. A replay will be available later the same day and archived for one year. Embecta, a global medical supplies company advancing its lega...
07-24 21:00
Mizuho Maintains Neutral on Embecta, Lowers Price Target to $12
Mizuho analyst Anthony Petrone maintains Embecta (NASDAQ:EMBC) with a Neutral and lowers the price target from $13 to $12.
07-16 20:25
embecta to Participate in Investor Events
Embecta Corp. announced that its management will participate in several investor events in 2025, including the Goldman Sachs Leveraged Finance and Credit Conference, Jefferies Global Healthcare Conference, Goldman Sachs Global Healthcare Conference, and Truist Securities MedTech Conference. These events feature one-on-one investor meetings and fireside sessions at various locations, with key details as follows: - **Goldman Sachs Tenth Annual Leve...
05-27 21:00
美股大行评级 | 潜在涨幅112.77%！Craig-Hallum上调PLAYSTUDIOS目标价至3美元，评级升至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1132955525493317632.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Craig-Hallum：上调PLAYSTUDIOS(MYPS)评级至"买入"，目标价从2美元升至3美元</p> <p>• Leerink Partners：上调Fulcrum Therapeutics(FULC)评级至"
05-24 08:40
Embecta Reaffirms 2025 Outlook With Up to $1.09B Revenue, Unveils Long-Term Plan to Cut $500M Debt
Embecta Corp. ("embecta"; "The Company") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host its inaugural Analyst and Investor Day today to showcase its phased approach
05-22 18:35
Embecta shares are trading lower. The company reported Q2 financial results.
Embecta shares are trading lower. The company reported Q2 financial results.
05-10 01:15
Why Is Embecta Stock Falling On Friday?
Embecta reaffirms earnings outlook, trims revenue forecast, and boosts cash flow as restructuring and cost controls offset tariff and FX headwinds.
05-10 00:10
Embecta reports FQ2 results
Embecta press release (NASDAQ:EMBC): FQ2 Non-GAAP EPS of $0.70. Revenue of $259M (-9.8% Y/Y). More on Embecta Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour Seeking Alph...
05-09 19:12
Embecta Affirms FY2025 Adj EPS Guidance of $2.70-$2.90 vs $2.80 Est; Lowers FY2025 Sales Guidance of $1.07B-$1.09B vs $1.09B Est
Embecta (NASDAQ:EMBC) affirms FY2025 Adj EPS guidance from $2.70-$2.90 to $2.70-$2.90 vs $2.80 analyst estimate. Lowers FY2025 sales outlook from $1.07 billion-$1.09 billion to $1.07 billion-$1.09 billion vs $1.09
05-09 18:32
Embecta Q2 Adj. EPS $0.70 Beats $0.53 Estimate, Sales $259.00M Beat $253.94M Estimate
Embecta (NASDAQ:EMBC) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.53 by 32.08 percent. This is a 4.48 percent increase over earnings of $0.67 per share from the same
05-09 18:31
